Synvest Imaging Inc.
Developer of an investigational fluorine-18 SV2A PET tracer intended to provide a quantitative measure of synaptic density for neurodegenerative and other CNS indications. Current stage: pre-clinical / IND-enabling with published first-in-human data, ongoing IND-enabling work, and licensed US composition-of-matter patent.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Fluorine-18 SV2A PET tracer (investigational)
An investigational F-18 labeled tracer targeting synaptic vesicle glycoprotein 2A (SV2A) designed to provide a direct, quantitative measure of synaptic density (V_T). Not approved for clinical use.
Fluorine-18 SV2A PET tracer (investigational)
An investigational F-18 labeled tracer targeting synaptic vesicle glycoprotein 2A (SV2A) designed to provide a direct, quantitative measure of synaptic density (V_T). Not approved for clinical use.
Services
Production and distribution services for fluorine-18 labeled radiopharmaceuticals via central radiopharmacies and existing 18F delivery networks.
Providing SV2A PET as an imaging biomarker for clinical trials and drug development programs, including imaging protocol support and collaboration.
Partnerships with academic investigators for cohort studies and investigator-initiated research using SV2A PET.
Production and distribution services for fluorine-18 labeled radiopharmaceuticals via central radiopharmacies and existing 18F delivery networks.
Providing SV2A PET as an imaging biomarker for clinical trials and drug development programs, including imaging protocol support and collaboration.
Partnerships with academic investigators for cohort studies and investigator-initiated research using SV2A PET.
Expertise Areas
- Radiopharmaceutical development
- PET neuroimaging
- Biomarker qualification and validation
- Radiochemistry and radiopharmacy distribution
Key Technologies
- Positron emission tomography (PET)
- Fluorine-18 radiochemistry
- SV2A-targeted PET tracers
- Quantitative PET V_T metrics
News & Updates
US composition-of-matter patent covering the tracer molecules; granted in 2022 and exclusively licensed to the company.
The fluorine-18 SV2A tracer was selected as the tracer for the FNIH Biomarkers Consortium SV2A PET Project to support biomarker qualification.
First-in-human publications reporting safety, biodistribution and dosimetry with test–retest variability under 9%.
Over 50 published human studies encompassing 1,700+ participants and 34 registered clinical trials across multiple indications.
US composition-of-matter patent covering the tracer molecules; granted in 2022 and exclusively licensed to the company.
The fluorine-18 SV2A tracer was selected as the tracer for the FNIH Biomarkers Consortium SV2A PET Project to support biomarker qualification.
First-in-human publications reporting safety, biodistribution and dosimetry with test–retest variability under 9%.
Over 50 published human studies encompassing 1,700+ participants and 34 registered clinical trials across multiple indications.